- Home
- CLW vs IGMS Comparison
CLW vs IGMS Comparison
Compare CLW & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- IGMS
- Stock Information
- Founded
- CLW 2005
- IGMS 1993
- Country
- CLW United States
- IGMS United States
- Employees
- CLW N/A
- IGMS N/A
- Industry
- CLW Paper
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- CLW Basic Materials
- IGMS Health Care
- Exchange
- CLW Nasdaq
- IGMS Nasdaq
- Market Cap
- CLW 444.7M
- IGMS 528.6M
- IPO Year
- CLW N/A
- IGMS 2019
- Fundamental
- Price
- CLW $30.27
- IGMS $6.90
- Analyst Decision
- CLW Buy
- IGMS Buy
- Analyst Count
- CLW 1
- IGMS 7
- Target Price
- CLW $37.00
- IGMS $17.43
- AVG Volume (30 Days)
- CLW 464.8K
- IGMS 219.5K
- Earning Date
- CLW 02-18-2025
- IGMS 11-08-2024
- Dividend Yield
- CLW N/A
- IGMS N/A
- EPS Growth
- CLW N/A
- IGMS N/A
- EPS
- CLW 0.88
- IGMS N/A
- Revenue
- CLW $2,211,900,000.00
- IGMS $2,918,000.00
- Revenue This Year
- CLW N/A
- IGMS $386.95
- Revenue Next Year
- CLW N/A
- IGMS N/A
- P/E Ratio
- CLW $257.28
- IGMS N/A
- Revenue Growth
- CLW 58.65
- IGMS 57.64
- 52 Week Low
- CLW $23.97
- IGMS $6.17
- 52 Week High
- CLW $57.13
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- CLW 67.03
- IGMS 29.48
- Support Level
- CLW $24.15
- IGMS $7.00
- Resistance Level
- CLW $26.00
- IGMS $10.80
- Average True Range (ATR)
- CLW 1.37
- IGMS 0.94
- MACD
- CLW 0.17
- IGMS -0.10
- Stochastic Oscillator
- CLW 85.95
- IGMS 2.98
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and selling of private label tissue, paperboard, and pulp-based products. The company has two reportable segments namely the consumer products segment which manufactures and sells a complete line of at-home tissue products as well as AFH products. The pulp and paperboard segment manufactures and markets bleached paperboard for the high-end segment of the packaging industry as well as offers services that include custom sheeting, slitting and cutting of paperboard. It generates maximum revenue from Pulp and Paperboard segment. Geographically, it derives maximum revenue from the United States.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.